Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea B Apolo

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysisAndrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
European Urology|June 26, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management ImplicationsCan Aydogdu, Laura Bukavina, Liang Cheng, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2016
Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate CancerAndrea B Apolo, Liza Lindenberg, Joanna H Shih, et al.
Nature Reviews. Urology|August 16, 2025
HER2 and urothelial carcinoma: current understanding and future directionsDaniele Raggi, Emanuele Crupi, Filippo Pederzoli, et al.
Journal of the National Cancer Institute|December 26, 2012
Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancerIndu Kohaar, Patricia Porter-Gill, Petra Lenz, et al.
Oncotarget|July 25, 2022
Predicting cancer immunotherapy response from gut microbiomes using machine learning modelsHai Liang, Jay-Hyun Jo, Zhiwei Zhang, et al.
Clinical Genitourinary Cancer|January 1, 2018
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder CancerLauren C Harshman, Abhishek Tripathi, Matthew Kaag, et al.
Future Oncology (London, England)|June 23, 2025
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationaleAndre R Kydd, Elias Chandran, Nicholas I Simon, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
BJU International|November 20, 2014
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancerFatima H Karzai, Andrea B Apolo, Liang Cao, et al.
The Lancet. Oncology|June 10, 2022
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trialRobert J Motzer, Thomas Powles, Mauricio Burotto, et al.
Journal for Immunotherapy of Cancer|October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysisAndrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
European Urology|June 26, 2026
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management ImplicationsCan Aydogdu, Laura Bukavina, Liang Cheng, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 23, 2016
Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate CancerAndrea B Apolo, Liza Lindenberg, Joanna H Shih, et al.
Nature Reviews. Urology|August 16, 2025
HER2 and urothelial carcinoma: current understanding and future directionsDaniele Raggi, Emanuele Crupi, Filippo Pederzoli, et al.
Journal of the National Cancer Institute|December 26, 2012
Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancerIndu Kohaar, Patricia Porter-Gill, Petra Lenz, et al.
Oncotarget|July 25, 2022
Predicting cancer immunotherapy response from gut microbiomes using machine learning modelsHai Liang, Jay-Hyun Jo, Zhiwei Zhang, et al.
Clinical Genitourinary Cancer|January 1, 2018
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder CancerLauren C Harshman, Abhishek Tripathi, Matthew Kaag, et al.
Future Oncology (London, England)|June 23, 2025
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationaleAndre R Kydd, Elias Chandran, Nicholas I Simon, et al.
Pageof 12